Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis

Breast Cancer Research and Treatment
Zhuo ZhangYimin Cui

Abstract

The extracellular domain (ECD) of human epidermal growth factor receptor-2 (HER2) in the blood is a promising biomarker of cancer prognosis and response to therapy, whereas the clinical prognostic role of serum HER2 ECD (sHER2 ECD) level in patients with BC remains controversial. Moreover, its cut-off value significantly varies. Thus, this meta-analysis aimed to quantify the prognostic impact of this biomarker with a specific cut-off value in patients with BC. A systematic review of electronic databases was conducted to identify studies that assessed the association between baseline sHER2 ECD level with a cut-off value of 15 ng/mL and clinical outcomes in patients with BC. Overall survival (OS) was the primary endpoint, and disease-free survival (DFS), progression-free survival (PFS), and time to progression (TTP) were the secondary endpoints. An inverse variance random effects meta-analysis was conducted. Twenty-three studies that included 8231 patients with BC who met the inclusion criteria were included. An elevated baseline sHER2 ECD level was associated with a hazard ratio (HR) of 2.28 (95% confidence interval [CI] 2.00-2.61; P < 0.001) for OS, and this effect was observed in all subgroups. The HRs for an elevated sHER2 EC...Continue Reading

References

Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Allan LiptonJ Allard
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A LiptonW Carney
Apr 19, 2007·Journal of the National Cancer Institute·Maurizio ScaltritiJosé Baselga
Jan 12, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V LudoviniL Crinò
Apr 26, 2008·Breast Cancer Research and Treatment·Vivien H C BramwellAnn F Chambers
Apr 3, 2010·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Rafael MolinaMartin Velasco
May 10, 2011·Cancer Treatment Reviews·Chantal TséPierre-Jean Lamy
Dec 3, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Dorit Di GioiaPetra Stieber
Feb 10, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lyndsay N HarrisUNKNOWN American Society of Clinical Oncology
May 30, 2017·Anticancer Research·Malgorzata Banys-PaluchowskiVolkmar Müller
Mar 2, 2018·Laboratory Investigation; a Journal of Technical Methods and Pathology·Alexandre PerrierMathieu Boissan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.